Nanohale AG (FYB) | WebDisclosure

Basculer en Français

8302	Companies
115168	Keywords
55488	Articles
62552	Press releases

Home
Companies
Nanohale AG

PRESS RELEASE

published on 07/26/2024 at 12:00, 3 months 26 days ago

Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 (Ustekinumab), a biosimilar candidate to Stelara®
Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 biosimilar candidate to Stelara. Approval expected in early Q4 2024. Biosimilars boost healthcare access & reduce costs globally

Biosimilar Formycon Fresenius Kabi FYB202 CHMP Opinion
BRIEF

published on 07/26/2024 at 10:59, 3 months 26 days ago

FYB202 Biosimilar to Stelara Receives Positive CHMP Opinion from EMA

Biosimilar Formycon FYB202 CHMP EMA
BRIEF

published on 07/26/2024 at 10:59, 3 months 26 days ago

Le biosimilaire FYB202 de Stelara reçoit un avis positif du CHMP de l'EMA

Formycon FYB202 Biosimilaire CHMP EMA
PRESS RELEASE

published on 07/26/2024 at 10:54, 3 months 26 days ago

EQS-Adhoc: Stelara® Biosimilar Candidate FYB202 (Ustekinumab) receives positive CHMP opinion from EMA
Formycon AG's biosimilar candidate FYB202 (Ustekinumab) for Stelara® receives a positive opinion from EMA's CHMP, recommended for EU approval for treating severe inflammatory diseases

Formycon AG Biosimilar FYB202 CHMP EMA
BRIEF

published on 07/01/2024 at 06:55, 4 months 21 days ago

Formycon Receives FDA Approval for Aflibercept Biosimilar

FDA Approval Biosimilar Formycon Retinal Diseases Ophthalmic Therapies
BRIEF

published on 07/01/2024 at 06:55, 4 months 21 days ago

Formycon reçoit l'approbation de la FDA pour le biosimilaire Aflibercept

Approbation De La FDA Formycon Biosimilaire Maladies De La Rétine Thérapies Ophtalmiques
PRESS RELEASE

published on 07/01/2024 at 06:50, 4 months 21 days ago

Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)
Formycon receives FDA approval for FYB203/AHZANTIVE(R) (aflibercept-mrbb), a biosimilar to Eylea(R). The approval highlights Formycon's expertise and commitment to providing effective and affordable biosimilar therapies for retinal diseases.

FDA Approval Biosimilar Formycon Eylea Retinal Diseases
BRIEF

published on 06/28/2024 at 23:55, 4 months 23 days ago

La FDA approuve le biosimilaire FYB203/AHZANTIVE® pour les maladies rétiniennes

Approbation De La FDA Biosimilaire Eylea Maladies De La Rétine Approbation Du Traitement
BRIEF

published on 06/28/2024 at 23:55, 4 months 23 days ago

FDA Approves Biosimilar FYB203/AHZANTIVE® for Retinal Diseases

FDA Approval Biosimilar Eylea Retinal Diseases Treatment Approval
PRESS RELEASE

published on 06/28/2024 at 23:50, 4 months 23 days ago

EQS-Adhoc: FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
FDA grants approval for Eylea biosimilar FYB203/AHZANTIVE by Formycon AG and Klinge Biopharma GmbH. Biosimilar approved for nAMD and other retinal diseases

FDA Approval Retinal Diseases Eylea Biosimilar FYB203/AHZANTIVE Neovascular Age-Related Macular Degeneration

Accesswire

Published on 11/22/2024 at 00:00, 9 hours 4 minutes ago

Gratomic Announces Company and Operational Update
Published on 11/21/2024 at 22:05, 10 hours 59 minutes ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 11 hours 14 minutes ago

Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 12 hours 49 minutes ago

Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 12 hours 54 minutes ago

For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform

View all ACCESSWIRE

EQS Group

Published on 11/22/2024 at 08:30, 34 minutes ago

Poland as an interesting development direction for German B2C e-commerce companies?
Published on 11/22/2024 at 08:12, 52 minutes ago

EQS-Adhoc: PVA TePla AG launches share buyback program to support strategic acquisitions and long-term compensation plans
Published on 11/22/2024 at 08:09, 54 minutes ago

Holding(s) in Company
Published on 11/22/2024 at 08:00, 1 hour 3 minutes ago

Q3 Trading Update
Published on 11/22/2024 at 08:00, 1 hour 3 minutes ago

Addition of Mr Alain Nydegger as an Eligible Participant under the Group’s Matching Share Plan 2025-2028

Les Echos

Published on 11/21/2024 at 06:58, 1 day 2 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 1 day 2 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 1 day 2 hours ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 1 day 12 hours ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 1 day 13 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE